Allergen Table

	Gluten	Shellfish	Egg	Fish	Peanut	Soy	Milk / Casein Caseinates	Milk / Lactose	Nuts	Celery	Mustard	Sesame	Sulfur dioxide and sulfites in concentrations higher than 10mg/kg	Lupin	Mollusc	Synthetic latex
Wax crayons and plastic wax																
Wood pencils																
Felt pens																
Jovi!Neon																
JoviDecor Metalic / Textil																
JoviDecor Glass / Glass neon																
Rubbers																
Classcolor chalks							Yes									
Classcolor Street chalks																
Finger paint																
School and liquid poster paint																
Glitter and phosphorescent poster paint																
Metalic poster paint																Yes
Watercolours																
Varnish																Yes
JoviDecor Acryl paint																Yes
Blandiver	Yes															
Modelling clay																
Patmache																
Air-hardening paste																
Cream and stick face paint																

Last update: January 2019 | For more information, please contact: **calidad@jovi.es**

JOVI S.A.
Avda. Bizet, 39-41. Pol. Ind. Can Jardí | 08191 Rubí (Barcelona) España
T. (+34) 93 588 53 93 | jovi@jovi.es | www.jovi.es

STUDY/TEST ELEMENT REFERENCES: 02/TC-PTS-1_092_19-004, 02/TC-PTS-1_092_19-005, 02/TC-PTS-1_092_19-006, 02/TC-PTS-1_092_19-007, 02/TC-PTS-1_092_19-008, 02/TC-PTS-1_092_19-009, 02/TC-PTS-1_092_19-010, 02/TC-PTS-1_092_19-011, 02/TC-PTS-1_092_19-012, 02/TC-PTS-1_092_19-013, 02/TC-PTS-1_092_19-014, 02/TC-PTS-1_092_19-015, 02/TC-PTS-1_092_19-016, 02/TC-PTS-1_092_19-017, 02/TC-PTS-1_092_19-018

Study Report - Version nº 1

ASSESSMENT IN HUMAN OF THE CUTANEOUS COMPATIBILITY OF A COSMETIC PRODUCT AFTER A SINGLE UNDER PATCH APPLICATION UNDER DERMATOLOGICAL CONTROL

SPONSOR: JOVI S.A.
TESTED ELEMENT: VARIOUS ELEMENTS
REFERENCE: VARIOUS REFERENCES

Madrid, November 7th, 2019

REPORT INDEX

1. SYNOPSYS

SPONSOR	JOVI S.A. AVDA. BIZET 39-41 08191 RUBÍ (BARCELONA)
Tested product	VARIOUS ELEMENTS
Date of order	October 15th, 2019
Testing Facility	ZURKO RESEARCH S.L. Almansa st 110, local 18, 28040 Madrid (Spain) Tel: (+34) 91.521.15.88
Supervisors of Study	Ana García Blanco, Biologist Javier Pedraz Muñoz, Dermatologist
Study code	Various study codes
Subjects	Number of Subjects enrolled: 13 Age range: 18-70 years Gender: both Skin type: sensitive skin according to center criteria Number of Subjects Completed: 13
Test area	Upper back
Application	Duration: 3 days Frequency: only once
Test period	October 23rd, 2019 – October 25th, 2019
Test parameters	Cutaneous evaluation of erythema and oedema
Design of study	Day 1 (0 hours) – Sample preparation and application Day 3 (48 hours) – Clinical and dermatological evaluation
Evaluation	Cutaneous Mean Irritation Index (M.I.I.)

2. IDENTIFICATION OF THE STUDY

Name of the study: Assessment in human of the cutaneous compatibility of a cosmetic product after a single under patch application under dermatological control (Patch test).

Director of the laboratory: Irene Zaldívar Notario.

Director of the study: María Barbero Calderón.

Sponsor: JOVI S.A.

Sponsor address: AVDA. BIZET 39-41 08191 RUBÍ (BARCELONA).

Tested element: VARIOUS FACE PAINT, reference: VARIOUS REFERENCES, batch: VARIOUS BATCH.

Information about the tested product is included in **Annex II**.

The identity and stability of the tested elements are in the product data sheet provided by JOVI S.A.

3. OBJECTIVE AND PRINCIPLE OF THE STUDY

The objective of this study is to verify the cutaneous compatibility of some cosmetic products after a single application on the skin under exaggerated experimental conditions.

The products were applied, only once, over the skin of the back and under an occlusive patch.

The compatibility of the products with the skin were verified, after 15-30 minutes of removing the patches and by means of visual exam of the experimental area, by the responsible technical expert, as well as by a dermatologist in charge for the study.

4. TYPE OF STUDY

This study has been carried out in the Experimental Center under dermatological control.

The negative control excluded false positives.

The study was carried out following general conditions in Zurko Research, established for the execution of study project on humans (Structure and Content of Clinical Study Reports from ICH Harmonised Tripartite Guideline; Guideline for good clinical practice E6 (R2) of June 14th 2017, EMA/CHMP/ICH/135/1995 of May 1st 1996, European Parliament and Council Guideline 2001/20/CE – May 1st 2001).

Previously, Zurko Research assessed the suitability of the product for the type of study and methodology to be employed.

5. RESEARCH CENTER AND TECHNICAL TEAM

5.1. Research Center

ZURKO RESEARCH S.L.

Almansa st 110, local 18

28040 Madrid (Spain)

Tel: (+34) 91.521.15.88

5.2. Technical Team

Director of the study: María Barbero Calderón, Pharmacist.

Researcher: Ana García Blanco, Biologist.

Technician: Soledad Gonzalo Muñoz, Ainhoa Yepes Agudo.

Dermatologist: Javier Pedraz Muñoz. Medical license number: 283706434.

6. STUDY EXECUTION SCHEDULE

Beginning of the experimental phase: October 23rd, 2019

Finalizing of the experimental phase: October 25th, 2019

7. VOLUNTEERS

7.1. Ethical aspects

Each volunteer participating in the study was previously informed about the type and procedures of the study, signing an informed consent before the start of the study. The original informed consents were filed with Zurko Research.

7.2. Number

13 volunteers were included in the study. The number of volunteers required at the end of the study was 10. Considering that the number of volunteers used in this type of study is sufficient to verify compatibility of a cosmetic dermal product.

No volunteer discontinued the study due to reasons unrelated to it. No exclusion was decided by the researcher.

The compatibility of the tested product was therefore verified on 13 volunteers.

All volunteers continued the following recommendations of the study's principal investigator:

- No intention to practice intense sport while the patch is on the back, that could produce intense sweating and affect the patch.
- No apply other cosmetic product in the experimental area

7.3. Specific inclusion and exclusion criteria

The specific inclusion criteria, defined in the protocol, were as follow:

- Age: 18-70 years old
- Sex: both
- Photo-type (Fitzpatrick): I to VI
- Skin type: sensitive skin according to the center criteria

All volunteers responded to the specific inclusion criteria. Their typology is defined in **Annex I.**

The specific exclusion criteria, defined in the protocol, were as follow:

- Cutaneous marks on the experimental area that could interfere with the evaluation of the skin reactions (pigmentation disruptions, scars, excessive hair areas, excessive freckles and moles, solar skin burns …).
- Tattoos, injuries, pathologies or infection in the experimental area.
- Eczematous reaction which has not fully disappeared, scar or pigmentation complications from previous studies in the experimental area.
- Intention to bath in the bath, swimming pool or the sea, or having sauna or Turkish baths during the study.
- Intense sun or UV rays exposure during the study or during the previous month to the study.

- Carrying out a treatment containing acid vitamin A or its by-products, during the 3 months previous to the study.
- Carrying out a treatment containing topical corticoids, on the experimental area during the 8 days previous to the beginning of the study.
- Treatment with any medicine for psoriasis, vitiligo, within one month before the study.
- Vaccination prediction during the study period or having had the last vaccine within the 3 weeks previous to the study.
- Being pregnant or breastfeeding.
- Allergies to metals.
- Reactivity to medical tape.
- Participation during the previous 30 days in any study under exaggerated conditions (under a patch).

None of the volunteers responded to these specific exclusion criteria.

8. EQUIPMENT

- Curatest® semiocclusive patch
- Finn Chamber Aqua® occlusive patch
- Pasteur pipettes 1ml
- Sterile containers
- Finn chamber tray
- Distilled water
- Micropipette Siner lab (Ref. HG20566) 20-200µl
- Tweezers
- Sanitary alcohol 70º
- Cotton
- Precision Balance Model: PS 750. R2. Radwag

9. METHODOLOGY

9.1. Criteria for application of the product

Type of product: leave on make-up cream.

Experimental area: upper back.

Product preparation: the sample is not diluted.

Applied quantity: 20 mg of product preparation over occlusive patch (Finn Chamber Aqua® occlusive patch).

Contact time: 48 hours.

Control time after patch removal: 15-30 minutes.

9.2. Experimental procedure

The first day of the test, the volunteers filled the informed consent and the exclusion criteria.

Day 1 (0 hours) – Sample preparation and application. The principal investigator examined the study area each participant and verify the inclusion criteria and none of the exclusion criteria.

After cleaning the experimental area, the product under study was applied to the patch on top of the back in occlusive conditions for 48 hours. One patch without product was applied in the same experimental conditions (negative control).

Day 3 (48 hours) – Clinical examination and scoring. Skin reactions were evaluated 15-30 minutes after patch removal according to the scores reported in table 1, which describes the severity of Erythema (E) and Oedema (OE) parameters.

Score	Assessment of reaction	PARAMETERS EVALUATED	
		Erythema (E)	Oedema (OE)
0	Absence	No erythema	No oedema
0,5	Doubtful	Very slight erythema (barely perceptible: quiet pinked coloration of one part of the tested area)	-
1	Slight	Slight erythema (quiet pinked coloration of the complete tested area or rather visible on one part of the tested area)	Slight oedema (palpable and visible)
2	Moderate	Obvious erythema (clear erythema covering all of the tested area)	Obvious oedema with or without papule/s or vesicle/s
3	Severe	Intense erythema (severe erythema covering all the tested area or erythema diffusing outside the tested area)	Intense oedema (extended area outside the tested area) with or without vesicle/s or blister/s

Table 1. Clinical examination and scoring

Other types of skin irritation could be observed (Dryness (D); Detergency (DT); Thickness (T); Reflectivity (R)) according to the following scale:

- 0,5 = doubtful
- 1 = Slight
- 2 = Moderate
- 3= Severe

The volunteers verified absence of reaction at 24 hours after patch removal. In the case that exits visible reaction, the subject must return to the center performing subsequent reads until his disappearance.

9.3. Interpretation of Results

The analysis and the interpretation of the results were carried out according to the results obtained in the experimental conditions. They were descriptive and completed by the calculation of the Mean Irritation Index (M.I.I.).

$$\text{M.I.I.} = \frac{\Sigma\,(\bar{x}\text{ of the grade erythema and oedema})}{\text{Number of volunteers}}$$

The obtained index was used to classify the studied cosmetic product according to the following scale:

M.I.I.	Product Classification
M.I.I.=0,000	Non Irritating (NI)/Very Good Cutaneous Compatibility
M.I.I.<0,200	Non Irritating (NI) / Good Cutaneous Compatibility
0,200≤M.I.I.<0,500	Slightly Irritating (SI) / Intermediate Cutaneous Compatibility
0,500≤M.I.I.<1,000	Moderately Irritating (NI) / Bad Cutaneous Compatibility
M.I.I.≥1,000	Irritating (I) / Very Bad Cutaneous Compatibility

Table 2. Product classification according M.I.I.

Individual values and the product class were taken into account to write a suitable conclusion under the study conditions.

10. RESULTS

The individual reading results are presented in **Annex III**.

Next table showed the M.I.I. at 15-30 minutes after removal of the patch.

Product name	Product reference	M.I.I.	Results	Number of reactive volunteers	Reactive volunteers %
FACE PAINT BLANCO	ART.17101	**0,000**	Non-Irritating (NI)/Very Good Cutaneous Compatibility	0	0%
FACE PAINT ROSA	ART.17107	**0,000**	Non-Irritating (NI)/Very Good Cutaneous Compatibility	0	0%
FACE PAINT AZUL	ART.17112	**0,000**	Non-Irritating (NI)/Very Good Cutaneous Compatibility	0	0%
FACE PAINT AMARILLO	ART.17102	**0,000**	Non-Irritating (NI)/Very Good Cutaneous Compatibility	0	0%
FACE PAINT VERDE	ART.17121	**0,038**	Non-Irritating (NI)/ Good Cutaneous Compatibility	1	8%
FACE PAINT AZUL OSCURO	ART.17113	**0,000**	Non-Irritating (NI)/Very Good Cutaneous Compatibility	0	0%
FACE PAINT NARANJA	ART.17104	**0,000**	Non-Irritating (NI)/Very Good Cutaneous Compatibility	0	0%
FACE PAINT VERDE	ART.17111	**0,000**	Non-Irritating (NI)/Very Good Cutaneous Compatibility	0	0%
FACE PAINT NEGRO	ART.17115	**0,000**	Non-Irritating (NI)/Very Good Cutaneous Compatibility	0	0%
FACE PAINT ROJO	ART.17105	**0,038**	Non-Irritating (NI)/Very Good Cutaneous Compatibility	1	8%
FACE PAINT VERDE OSCURO	ART.17110	**0,000**	Non-Irritating (NI)/Very Good Cutaneous Compatibility	0	0%
FACE PAINT GRIS	ART.17137	**0,000**	Non-Irritating (NI)/Very Good Cutaneous Compatibility	0	0%
FACE PAINT MARRON	ART.17109	**0,000**	Non-Irritating (NI)/Very Good Cutaneous Compatibility	0	0%
FACE PAINT MORADO	ART.17114	**0,000**	Non-Irritating (NI)/Very Good Cutaneous Compatibility	0	0%
FACE PAINT DORADO	ART.17138	**0,000**	Non-Irritating (NI)/Very Good Cutaneous Compatibility	0	0%

11. CONCLUSION

Under adopted experimental conditions, the product**, FACE PAINT BLANCO,** reference: **ART.17101** is **Non irritating.** In conclusion, it has a **Very Good Cutaneous Compatibility.**

Under adopted experimental conditions, the product**, FACE PAINT ROSA,** reference: **ART.17107** is **Non irritating.** In conclusion, it has a **Very Good Cutaneous Compatibility.**

Under adopted experimental conditions, the product**, FACE PAINT AZUL,** reference: **ART.17112** is **Non irritating.** In conclusion, it has a **Very Good Cutaneous Compatibility.**

Under adopted experimental conditions, the product**, FACE PAINT AMARILLO,** reference: **ART.17102** is **Non irritating.** In conclusion, it has a **Very Good Cutaneous Compatibility.**

Under adopted experimental conditions, the product**, FACE PAINT VERDE,** reference: **ART.17121** is **Non irritating.** In conclusion, it has a **Good Cutaneous Compatibility.**

Under adopted experimental conditions, the product**, FACE PAINT AZUL OSCURO,** reference: **ART.17113** is **Non irritating.** In conclusion, it has a **Very Good Cutaneous Compatibility.**

Under adopted experimental conditions, the product**, FACE PAINT NARANJA,** reference: **ART.17104** is **Non irritating.** In conclusion, it has a **Very Good Cutaneous Compatibility.**

Under adopted experimental conditions, the product**, FACE PAINT VERDE,** reference: **ART.17111** is **Non irritating.** In conclusion, it has a **Very Good Cutaneous Compatibility.**

Under adopted experimental conditions, the product**, FACE PAINT NEGRO,** reference: **ART.17115** is **Non irritating.** In conclusion, it has a **Very Good Cutaneous Compatibility.**

Under adopted experimental conditions, the product**, FACE PAINT ROJO,** reference: **ART.17105** is **Non irritating.** In conclusion, it has a **Good Cutaneous Compatibility.**

Under adopted experimental conditions, the product**, FACE PAINT VERDE OSCURO,** reference: **ART.17110** is **Non irritating.** In conclusion, it has a **Very Good Cutaneous Compatibility.**

Under adopted experimental conditions, the product**, FACE PAINT GRIS,** reference: **ART.17137** is **Non irritating.** In conclusion, it has a **Very Good Cutaneous Compatibility.**

Under adopted experimental conditions, the product**, FACE PAINT MARRON,** reference: **ART.17109** is **Non irritating.** In conclusion, it has a **Very Good Cutaneous Compatibility.**

Under adopted experimental conditions, the product**, FACE PAINT MORADO,** reference: **ART.17114** is **Non irritating.** In conclusion, it has a **Very Good Cutaneous Compatibility.**

Under adopted experimental conditions, the product**, FACE PAINT DORADO,** reference: **ART.17138** is **Non irritating.** In conclusion, it has a **Very Good Cutaneous Compatibility.**

12. SAMPLES AND DOCUMENTS TO BE STORED

The following documents related to the study will be stored in the facilities of Zurko Research following the provisions of ISO 9001:2015:

- Study protocol and its modifications (Signed)
- Primary data
- Final report
- Documents provided by the sponsor

The documents will be stored for a period of 5 years. After 5 years the sponsor will be asked about the possibility of extension because of the commercialization of the tested element.

A sample of the tested product (sufficient quantity for the execution of the study) will be stored in the Zurko Research archive for samples, for 1 year from the start date of the study.

13. BIBLIOGRAPHICAL REFERENCES

1. SCCS (Scientific Committee on Consumer Safety), SCCS Notes of Guidance for the Testing of Cosmetic Ingredients and their Safety Evaluation.

2. Patel, S.M., E. Patrick, and H.I. Maibach, 1976 "Animal, Human, and In Vitro Test Methods for Predicting Skin Irritation". Dermatotoxicology, Chpt. 33; 5th Ed., F.N. Marzulli; H.I. Maibach; Taylor and Frances.

3. Holdiness, M.R., 1989, "A Review of Contact Dermatitis Associated with Transdermal Therapeutic Systems". Contact Dermatitis, 20(1);3-9.

4. North American Contact Dermatitis Group Patch-Test Results, 2001-2002 Study Period. Dermatitis: December 2004. Marks, James G. Jr; Belsito, Donald V.; DeLeo, Vincent A.; Fowler, Joseph F. Jr; Fransway, Anthony F.; Maibach, Howard I.; Mathias, Toby C.G.; Nethercott, James R.; Rietschel, Robert L.; Rosenthal, Lawrence E.; Sherertz, Elizabeth F.; Storrs, Frances J.; Taylor, James S.

5. Nueva Clasificación de tipos piel y sus implicaciones en Dermatología Cosmética. Revisión Dermatología Venezolana. Vol. 43, Nº 4, 2005. Leslie Baumann, Sadegh Amini, Eduardo Weiss.

SIGNATURES

Researcher: Ana García Blanco, Biologist. I, the undersigned, Ana García Blanco, declare that this study has been carried out under my responsibility and in the essence of the Clinical Good Practices (Guideline for good clinical practice E6 (R2) of June 14th 2017, EMA/CHMP/ICH/135/1995 of May 1st 1996, European Parliament and Council Guideline 2001/20/CE – May 1st 2001).

The results here presented reflect accurately and completely the raw data of the study.

Signature:

Dermatologist: Javier Pedraz Muñoz. Medical license number: 283706434.

Signature:



Responsible of the Area of Quality Management: Andrea Gómez Herranz, **Quality Guarantee Technician.** I, the undersigned, Andrea Gómez Herranz, declare that this study has been carried out under my responsibility and under the principles of ICH Good Clinical Practice (Guideline for good clinical practice E6 (R2) of June 14th 2017, EMA/CHMP/ICH/135/1995 of May 1st 1996, European Parliament and Council Guideline 2001/20/CE – May 1st 2001)

The inspections that have been made, allow to confirm that the final report reflects accurately the primary data of the study.

Signature:

ANNEXES

info@zurkoresearch.com • www.zurkoresearch.com

Annex I. Information relating to volunteers

Volunteers		Age (Years)	Sex (F/M)	Phototype	Skin Type (R/S)
Ref.	Acronym				
1	V1	56	F	III	S
2	V2	66	F	II	S
3	V3	33	F	IV	S
4	V4	65	F	III	S
5	V5	26	F	III	S
6	V6	65	M	III	S
7	V7	31	M	IV	S
8	V8	36	F	II	S
9	V9	39	M	IV	S
10	V10	41	F	II	S
11	V11	39	F	IV	S
12	V12	48	F	II	S
13	V13	62	F	V	S

F=female; M=male; R = resistant; S= sensitive

Annex II. Information about the tested products

Product Name	Product Reference	Batch
FACE PAINT BLANCO	ART.17101	115044-1
FACE PAINT ROSA	ART.17107	115048-1
FACE PAINT AZUL	ART.17112	115050-1
FACE PAINT AMARILLO	ART.17102	115045-1
FACE PAINT VERDE	ART.17121	115057-1
FACE PAINT AZUL OSCURO	ART.17113	115053-1
FACE PAINT NARANJA	ART.17104	115049-1
FACE PAINT VERDE	ART.17111	115052-1
FACE PAINT NEGRO	ART.17115	115051-1
FACE PAINT ROJO	ART.17105	115046-1
FACE PAINT VERDE OSCURO	ART.17110	115058-1
FACE PAINT GRIS	ART.17137	115054-1
FACE PAINT MARRON	ART.17109	115047-1
FACE PAINT MORADO	ART.17114	115056-1
FACE PAINT DORADO	ART.17138	115055-1

Annex III. Individual Results at 15-30 minutes after removal patch

02/TC-PTS-1_092_19-004

Volunteers		Erythema (E)		Oedema (OE)		Other Skin Alteration (D; DT; T; R)
Ref.	**Acronym**	Tested Product	Control	Tested Product	Control	
1	V1	0	0	0	0	-
2	V2	0	0	0	0	-
3	V3	0	0	0	0	-
4	V4	0	0	0	0	-
5	V5	0	0	0	0	-
6	V6	0	0	0	0	-
7	V7	0	0	0	0	-
8	V8	0	0	0	0	-
9	V9	0	0	0	0	-
10	V10	0	0	0	0	-
11	V11	0	0	0	0	-
12	V12	0	0	0	0	-
13	V13	0	0	0	0	-
M.I.I.		0,000		0,000		
M.I.I. Total		0,000				

D = Dryness; DT = Detergency; T = Thickness; R = Reflectivity

02/TC-PTS-1_092_19-005

Volunteers		Erythema (E)		Oedema (OE)		Other Skin Alteration (D; DT; T; R)
Ref.	**Acronym**	Tested Product	Control	Tested Product	Control	
1	V1	0	0	0	0	-
2	V2	0	0	0	0	-
3	V3	0	0	0	0	-
4	V4	0	0	0	0	-
5	V5	0	0	0	0	-
6	V6	0	0	0	0	-
7	V7	0	0	0	0	-
8	V8	0	0	0	0	-
9	V9	0	0	0	0	-
10	V10	0	0	0	0	-
11	V11	0	0	0	0	-
12	V12	0	0	0	0	-
13	V13	0	0	0	0	-
M.I.I.		0,000		0,000		
M.I.I. Total		0,000				

D = Dryness; DT = Detergency; T = Thickness; R = Reflectivity

02/TC-PTS-1_092_19-006

Volunteers		Erythema (E)		Oedema (OE)		Other Skin Alteration (D; DT; T; R)
Ref.	**Acronym**	Tested Product	Control	Tested Product	Control	
1	V1	0	0	0	0	-
2	V2	0	0	0	0	-
3	V3	0	0	0	0	-
4	V4	0	0	0	0	-
5	V5	0	0	0	0	-
6	V6	0	0	0	0	-
7	V7	0	0	0	0	-
8	V8	0	0	0	0	-
9	V9	0	0	0	0	-
10	V10	0	0	0	0	-
11	V11	0	0	0	0	-
12	V12	0	0	0	0	-
13	V13	0	0	0	0	-
M.I.I.		0,000		0,000		
M.I.I. Total		0,000				

D = Dryness; DT = Detergency; T = Thickness; R = Reflectivity

02/TC-PTS-1_092_19-007

Volunteers		Erythema (E)		Oedema (OE)		Other Skin Alteration (D; DT; T; R)
Ref.	**Acronym**	Tested Product	Control	Tested Product	Control	
1	V1	0	0	0	0	-
2	V2	0	0	0	0	-
3	V3	0	0	0	0	-
4	V4	0	0	0	0	-
5	V5	0	0	0	0	-
6	V6	0	0	0	0	-
7	V7	0	0	0	0	-
8	V8	0	0	0	0	-
9	V9	0	0	0	0	-
10	V10	0	0	0	0	-
11	V11	0	0	0	0	-
12	V12	0	0	0	0	-
13	V13	0	0	0	0	-
M.I.I.		0,000		0,000		
M.I.I. Total		0,000				

D = Dryness; DT = Detergency; T = Thickness; R = Reflectivity

02/TC-PTS-1_092_19-008

Volunteers		Erythema (E)		Oedema (OE)		Other Skin Alteration (D; DT; T; R)
Ref.	**Acronym**	Tested Product	Control	Tested Product	Control	
1	V1	0	0	0	0	-
2	V2	0	0	0	0	-
3	V3	0	0	0	0	-
4	V4	0	0	0	0	-
5	V5	0	0	0	0	-
6	V6	0	0	0	0	-
7	V7	0	0	0	0	-
8	V8	0	0	0	0	-
9	V9	1	0	0	0	-
10	V10	0	0	0	0	-
11	V11	0	0	0	0	-
12	V12	0	0	0	0	-
13	V13	0	0	0	0	-
M.I.I.		0,077		0,000		
M.I.I. Total		0,038				

D = Dryness; DT = Detergency; T = Thickness; R = Reflectivity

02/TC-PTS-1_092_19-009

Volunteers		Erythema (E)		Oedema (OE)		Other Skin Alteration (D; DT; T; R)
Ref.	**Acronym**	Tested Product	Control	Tested Product	Control	
1	V1	0	0	0	0	-
2	V2	0	0	0	0	-
3	V3	0	0	0	0	-
4	V4	0	0	0	0	-
5	V5	0	0	0	0	-
6	V6	0	0	0	0	-
7	V7	0	0	0	0	-
8	V8	0	0	0	0	-
9	V9	0	0	0	0	-
10	V10	0	0	0	0	-
11	V11	0	0	0	0	-
12	V12	0	0	0	0	-
13	V13	0	0	0	0	-
M.I.I.		0,000		0,000		
M.I.I. Total		0,000				

D = Dryness; DT = Detergency; T = Thickness; R = Reflectivity

02/TC-PTS-1_092_19-010

Volunteers		Erythema (E)		Oedema (OE)		Other Skin Alteration (D; DT; T; R)
Ref.	**Acronym**	Tested Product	Control	Tested Product	Control	
1	V1	0	0	0	0	-
2	V2	0	0	0	0	-
3	V3	0	0	0	0	-
4	V4	0	0	0	0	-
5	V5	0	0	0	0	-
6	V6	0	0	0	0	-
7	V7	0	0	0	0	-
8	V8	0	0	0	0	-
9	V9	0	0	0	0	-
10	V10	0	0	0	0	-
11	V11	0	0	0	0	-
12	V12	0	0	0	0	-
13	V13	0	0	0	0	-
M.I.I.		0,000		0,000		
M.I.I. Total		0,000				

D = Dryness; DT = Detergency; T = Thickness; R = Reflectivity

02/TC-PTS-1_092_19-011

Volunteers		Erythema (E)		Oedema (OE)		Other Skin Alteration (D; DT; T; R)
Ref.	**Acronym**	Tested Product	Control	Tested Product	Control	
1	V1	0	0	0	0	-
2	V2	0	0	0	0	-
3	V3	0	0	0	0	-
4	V4	0	0	0	0	-
5	V5	0	0	0	0	-
6	V6	0	0	0	0	-
7	V7	0	0	0	0	-
8	V8	0	0	0	0	-
9	V9	0	0	0	0	-
10	V10	0	0	0	0	-
11	V11	0	0	0	0	-
12	V12	0	0	0	0	-
13	V13	0	0	0	0	-
M.I.I.		0,000		0,000		
M.I.I. Total		0,000				

D = Dryness; DT = Detergency; T = Thickness; R = Reflectivity

02/TC-PTS-1_092_19-012

Volunteers		Erythema (E)		Oedema (OE)		Other Skin Alteration (D; DT; T; R)
Ref.	**Acronym**	Tested Product	Control	Tested Product	Control	
1	V1	0	0	0	0	-
2	V2	0	0	0	0	-
3	V3	0	0	0	0	-
4	V4	0	0	0	0	-
5	V5	0	0	0	0	-
6	V6	0	0	0	0	-
7	V7	0	0	0	0	-
8	V8	0	0	0	0	-
9	V9	0	0	0	0	-
10	V10	0	0	0	0	-
11	V11	0	0	0	0	-
12	V12	0	0	0	0	-
13	V13	0	0	0	0	-
M.I.I.		0,000		0,000		
M.I.I. Total		0,000				

D = Dryness; DT = Detergency; T = Thickness; R = Reflectivity

02/TC-PTS-1_092_19-013

Volunteers		Erythema (E)		Oedema (OE)		Other Skin Alteration (D; DT; T; R)
Ref.	**Acronym**	Tested Product	Control	Tested Product	Control	
1	V1	0	0	0	0	-
2	V2	0	0	0	0	-
3	V3	0	0	0	0	-
4	V4	0	0	0	0	-
5	V5	0	0	0	0	-
6	V6	0	0	0	0	-
7	V7	0	0	0	0	-
8	V8	0	0	0	0	-
9	V9	1	0	0	0	-
10	V10	0	0	0	0	-
11	V11	0	0	0	0	-
12	V12	0	0	0	0	-
13	V13	0	0	0	0	-
M.I.I.		0,077		0,000		
M.I.I. Total		0,038				

D = Dryness; DT = Detergency; T = Thickness; R = Reflectivity

02/TC-PTS-1_092_19-014

Volunteers		Erythema (E)		Oedema (OE)		Other Skin Alteration (D; DT; T; R)
Ref.	**Acronym**	Tested Product	Control	Tested Product	Control	
1	V1	0	0	0	0	-
2	V2	0	0	0	0	-
3	V3	0	0	0	0	-
4	V4	0	0	0	0	-
5	V5	0	0	0	0	-
6	V6	0	0	0	0	-
7	V7	0	0	0	0	-
8	V8	0	0	0	0	-
9	V9	0	0	0	0	-
10	V10	0	0	0	0	-
11	V11	0	0	0	0	-
12	V12	0	0	0	0	-
13	V13	0	0	0	0	-
M.I.I.		0,000		0,000		
M.I.I. Total		0,000				

D = Dryness; DT = Detergency; T = Thickness; R = Reflectivity

02/TC-PTS-1_092_19-015

Volunteers		Erythema (E)		Oedema (OE)		Other Skin Alteration (D; DT; T; R)
Ref.	**Acronym**	Tested Product	Control	Tested Product	Control	
1	V1	0	0	0	0	-
2	V2	0	0	0	0	-
3	V3	0	0	0	0	-
4	V4	0	0	0	0	-
5	V5	0	0	0	0	-
6	V6	0	0	0	0	-
7	V7	0	0	0	0	-
8	V8	0	0	0	0	-
9	V9	0	0	0	0	-
10	V10	0	0	0	0	-
11	V11	0	0	0	0	-
12	V12	0	0	0	0	-
13	V13	0	0	0	0	-
M.I.I.		0,000		0,000		
M.I.I. Total		0,000				

D = Dryness; DT = Detergency; T = Thickness; R = Reflectivity

02/TC-PTS-1_092_19-016

Volunteers		Erythema (E)		Oedema (OE)		Other Skin Alteration (D; DT; T; R)
Ref.	**Acronym**	Tested Product	Control	Tested Product	Control	
1	V1	0	0	0	0	-
2	V2	0	0	0	0	-
3	V3	0	0	0	0	-
4	V4	0	0	0	0	-
5	V5	0	0	0	0	-
6	V6	0	0	0	0	-
7	V7	0	0	0	0	-
8	V8	0	0	0	0	-
9	V9	0	0	0	0	-
10	V10	0	0	0	0	-
11	V11	0	0	0	0	-
12	V12	0	0	0	0	-
13	V13	0	0	0	0	-
M.I.I.		0,000		0,000		
M.I.I. Total		0,000				

D = Dryness; DT = Detergency; T = Thickness; R = Reflectivity

info@zurkoresearch.com • www.zurkoresearch.com

02/TC-PTS-1_092_19-017

Volunteers		Erythema (E)		Oedema (OE)		Other Skin Alteration (D; DT; T; R)
Ref.	**Acronym**	Tested Product	Control	Tested Product	Control	
1	V1	0	0	0	0	-
2	V2	0	0	0	0	-
3	V3	0	0	0	0	-
4	V4	0	0	0	0	-
5	V5	0	0	0	0	-
6	V6	0	0	0	0	-
7	V7	0	0	0	0	-
8	V8	0	0	0	0	-
9	V9	0	0	0	0	-
10	V10	0	0	0	0	-
11	V11	0	0	0	0	-
12	V12	0	0	0	0	-
13	V13	0	0	0	0	-
M.I.I.		0,000		0,000		
M.I.I. Total		0,000				

D = Dryness; DT = Detergency; T = Thickness; R = Reflectivity

02/TC-PTS-1_092_19-018

Volunteers		Erythema (E)		Oedema (OE)		Other Skin Alteration (D; DT; T; R)
Ref.	**Acronym**	Tested Product	Control	Tested Product	Control	
1	V1	0	0	0	0	-
2	V2	0	0	0	0	-
3	V3	0	0	0	0	-
4	V4	0	0	0	0	-
5	V5	0	0	0	0	-
6	V6	0	0	0	0	-
7	V7	0	0	0	0	-
8	V8	0	0	0	0	-
9	V9	0	0	0	0	-
10	V10	0	0	0	0	-
11	V11	0	0	0	0	-
12	V12	0	0	0	0	-
13	V13	0	0	0	0	-
M.I.I.		0,000		0,000		
M.I.I. Total		0,000				

D = Dryness; DT = Detergency; T = Thickness; R = Reflectivity